Skip to main content

Bruker Sells $240M in Senior Notes

NEW YORK (GenomeWeb News) – Bruker has sold $240 million worth of senior notes through a private placement, it said in a filing with the US Securities and Exchange Commission Thursday.

The firm sold four series of notes in the placement: $20 million of 3.16 percent Series 2012A Senior Notes, Tranche A, due Jan. 18, 2017; $15 million of 3.74 percent Series 2012A Senior Notes, Tranche B, due Jan. 18, 2019; $105 million of 4.31 percent Series 2012A Senior Notes, Tranche C, due Jan. 18, 2022; and $100 million of 4.46 percent Series 2012A Senior Notes, Tranche D, due Jan. 18, 2024.

Bruker noted that under the terms of the note purchase agreement it may sell additional senior notes up to an aggregate amount of $600 million.

It intends to use the proceeds to reduce outstanding debt under its revolving credit facilities and for general corporate purposes.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.